Net Deals Web Search

Search results

1. Results From The WOW.Com Content Network

2. Travoprost - Wikipedia

   en.wikipedia.org/wiki/Travoprost

   Travoprost, sold under the brand name Travatan among others, is a medication used to treat high pressure inside the eye including glaucoma. [4] Specifically it is used for open angle glaucoma when other agents are not sufficient. [5] [4] It is used as an eye drop. [4] Effects generally occur within two hours.

3. Dorzolamide - Wikipedia

   en.wikipedia.org/wiki/Dorzolamide

   Dorzolamide. Dorzolamide, sold under the brand name Trusopt among others, is a medication used to treat high pressure inside the eye, including in cases of glaucoma. [3] It is used as an eye drop. [3] Effects begin within three hours and last for at least eight hours. [3] It is also available as the combination dorzolamide/timolol.

4. Tobramycin/dexamethasone - Wikipedia

   en.wikipedia.org/wiki/Tobramycin/dexamethasone

   Tobramycin/dexamethasone, sold under the brand name Tobradex, is a fixed-dose combination medication in the form of eye drops and eye ointment, marketed by Alcon. [1] [2] [3] The active ingredients are tobramycin (an antibiotic) and dexamethasone (a corticosteroid ). [2] It is prescribed for the treatment of pink eye in combination with ...

5. Alcon (ALC) Launches Preservative-Free Drops for Dry Eye Relief

   www.aol.com/news/alcon-alc-launches-preservative...

   Alcon's (ALC) new preservative-free solution for patients with dry eye symptoms is the latest addition to its leading global artificial tear brand Systane.

6. The FDA Has Issued Another Warning About Eye Drops - AOL

   www.aol.com/full-list-recalled-eye-drops...

   Leader Lubricant Eye Drops 15 ml (single pack), NDC number 70000-0090-1. Leader Dry Eye Relief 10 ml, NDC number 70000-0088-1. Leader Eye Irritation Relief 15 ml, NDC number 70000-0087-1.

7. UPDATE 1-Alcon agrees $475 million deal to buy U.S. eye ... - AOL

   www.aol.com/news/1-alcon-agrees-475-million...

   Alcon has agreed to buy Ivantis, the maker of a tiny stent to treat glaucoma, for an initial $475 million, the Swiss eye care company said on Monday. Privately held Ivantis Hydrus Microstent makes ...